Nomic Bio struck a deal with Broad Clinical Labs to integrate its Nomic Omni 1000 proteomics immunoassay platform into BCL’s omics risk modeling workflows. Under the partnership, BCL will use the Omni 1000 platform to add quantitative proteomics data to genomic disease risk models, precision oncology pipelines, and clinical trial and population-scale multiomic studies. The Omni 1000 platform uses a bead-based nELISA technology for multiplexed immunoassays with absolute quantification across more than 1,050 proteins. Nomic said initial development work with BCL is underway, with joint applications planned to begin in early 2027. The collaboration directly addresses a key scalability bottleneck in proteomics, aiming to make proteomic readouts as operationally comparable to sequencing-based modalities within clinical research programs.